These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17289896)

  • 1. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
    Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
    Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
    McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
    J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism.
    Wilson ME
    J Clin Endocrinol Metab; 1998 Nov; 83(11):4013-21. PubMed ID: 9814485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
    Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
    Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
    Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome.
    Akintoye SO; Kelly MH; Brillante B; Cherman N; Turner S; Butman JA; Robey PG; Collins MT
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2960-6. PubMed ID: 16720661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GH receptor blocker administration and muscle-tendon collagen synthesis in humans.
    Nielsen RH; Doessing S; Goto K; Holm L; Reitelseder S; Agergaard J; Schjerling P; Flyvberg A; Kjaer M
    Growth Horm IGF Res; 2011 Jun; 21(3):140-5. PubMed ID: 21498100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH.
    Hansen TK; Thiel S; Dall R; Rosenfalck AM; Trainer P; Flyvbjerg A; Jørgensen JO; Christiansen JS
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5383-8. PubMed ID: 11701711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.
    Parkinson C; Drake WM; Roberts ME; Meeran K; Besser GM; Trainer PJ
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1797-804. PubMed ID: 11932320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).
    Berg CA; Pokrajac A; Bidlingmaier M; Strasburger CJ; Shalet SM; Trainer PJ
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):439-45. PubMed ID: 19067728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization.
    Parkinson C; Flyvbjerg A; Trainer PJ
    Growth Horm IGF Res; 2004 Feb; 14(1):59-65. PubMed ID: 14700556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
    Zgliczyński W; Zdunowski P
    Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor I (IGF-I) replacement during growth hormone receptor antagonism normalizes serum IGF-binding protein-3 and markers of bone formation in ovariectomized rhesus monkeys.
    Wilson ME
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1557-62. PubMed ID: 10770197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
    Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
    Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
    Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.